Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C30H62NO7P
Numéro CAS:
Poids moléculaire :
579.79
MDL number:
UNSPSC Code:
51191904
NACRES:
NA.25
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderdescription
1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine
assay
>99% (LPC; may contain up to 10% of the 2-LPC isomer, TLC)
form
powder
packaging
pkg of 1 × 25 mg (855779P-25mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
shipped in
dry ice
storage temp.
−20°C
SMILES string
O[C@](COP([O-])(OCC[N+](C)(C)C)=O)([H])COC(CCCCCCCCCCCCCCCCCCCCC)=O
InChI
1S/C30H62NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-30(33)36-27-29(32)28-38-39(34,35)37-26-25-31(2,3)4/h29,32H,5-28H2,1-4H3/t29-/m1/s1
InChI key
UIINDYGXBHJQHX-GDLZYMKVSA-N
Application
22:0 Lyso PC may be used as a standard to screen X-linked adrenoleukodystrophy (X-ALD) in newborns using positive ion electrospray (ESI) combined liquid chromatography-tandem spectrometric (LC-MS/MS) technique.
Packaging
5 mL Amber Glass Screw Cap Vial (855779P-25mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Classe de stockage
11 - Combustible Solids
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method
Hubbard WC, et al.
Molecular Genetics and Metabolism, 97(3), 212-220 (2009)
Walter C Hubbard et al.
Molecular genetics and metabolism, 89(1-2), 185-187 (2006-07-11)
Utilizing combined liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the analytical method, we have demonstrated a ten to sixtyfold excess of lysophosphatidyl choline containing hexacosanoic acid (26:0) in dried blood spots on a filter paper matrix from 25 male patients with
Kelsey B Law et al.
Autophagy, 13(5), 868-884 (2017-05-20)
Peroxisome biogenesis disorders (PBDs) are metabolic disorders caused by the loss of peroxisomes. The majority of PBDs result from mutation in one of 3 genes that encode for the peroxisomal AAA ATPase complex (AAA-complex) required for cycling PEX5 for peroxisomal
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| 855779P-25MG | 04061835231768 |